Submit Your Abstract

Abstracts must not exceed 300 words, excluding the title and author list. The live word counter in the submission form will alert you when you approach the limit.

Use the four-section structure: Background (context and rationale), Methods (study design, patient cohort, equipment, statistical analysis), Results (quantitative findings), and Conclusion (clinical or scientific significance).

All abstracts must be submitted in English. Proofread carefully — abstracts are published in the congress proceedings exactly as submitted. Abbreviations must be defined at first use.

Work must be original and not previously published in a peer-reviewed journal or presented at another international congress. Simultaneous submission to other meetings is not permitted.

The submitting author is responsible for obtaining written consent from all co-authors prior to submission. By submitting, you confirm that all listed authors have reviewed and approved the abstract.

Research involving human subjects, patient data, or animals must have received appropriate institutional ethics committee or IRB approval. State the approval reference number in the Methods section.

All financial relationships, speaker fees, research grants, and potential conflicts of interest must be disclosed at the time of submission. State 'None' if no conflicts exist.

Abstracts reporting clinical trial results must include the trial registration number (e.g. ClinicalTrials.gov, ISRCTN). Case reports must include patient consent confirmation.

Treatment outcomes, phase II/III clinical trials, tumour-site-specific protocols (head & neck, lung, breast, GI, GU, CNS, gynaecological), palliative radiotherapy, re-irradiation, and multidisciplinary management.

Advanced dosimetry, treatment planning systems, quality assurance, commissioning of modern radiotherapy equipment, stereotactic radiosurgery (SRS/SBRT), brachytherapy physics, and radiation protection.

Cellular and molecular mechanisms governing radiotherapy response and resistance, fractionation and hypofractionation biology, normal-tissue toxicity, radiogenomics, and biomarker discovery.

Adaptive radiotherapy, AI-assisted contouring and treatment planning, MR-Linac, proton and heavy-ion therapy, FLASH RT, surface-guided RT, and emerging delivery platforms.